Form 4: Opus Genetics SVP of Finance, Amy Zaremba Rabourn, Reports Acquisition of Stock Options and Restricted Stock Units
SEC Form 4 Filing
Amy Zaremba Rabourn, SVP of Finance at Opus Genetics, reports the acquisition of stock options and restricted stock units in the company.
Summary
- On March 13, 2025, Amy Zaremba Rabourn, SVP of Finance at Opus Genetics, acquired 39,500 shares of common stock through restricted stock units.
- These restricted stock units vest in four equal installments annually, starting on March 13, 2026, contingent upon continued service.
- Rabourn also acquired options to purchase 39,500 shares of common stock at an exercise price of $0.93 per share.
- These options vest 25% on March 13, 2026, with the remaining shares vesting quarterly over the subsequent 12 quarters, also subject to continued service.
- Following these transactions, Rabourn directly owns 113,968 shares of Opus Genetics common stock and options to purchase 39,500 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management and shareholder interests.
Positives
- The grant of stock options and restricted stock units aligns the SVP of Finance's interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to the company's long-term success.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects standard practices for incentivizing key personnel.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
- Vesting schedules, such as the four-year vesting period for the restricted stock units and the combination of cliff and quarterly vesting for the options, are typical in similar companies.
- Comparable companies like Spark Therapeutics or BioMarin Pharmaceutical also utilize equity-based compensation to attract and retain key employees.
Stakeholder Impact
- The grant of equity to the SVP of Finance could positively impact shareholder value by incentivizing strong leadership and long-term commitment.
- Employees may view this as a positive sign of investment in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 03/13/2025 | Date of transaction: grant of restricted stock units and stock options. |
| 03/13/2026 | First vesting date for both restricted stock units and 25% of the stock options. |
| 03/12/2035 | Expiration date of the employee stock options. |
| 03/17/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.